Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Nilotinib Lowers the Incidence of BCR-ABL Mutations and Improves the Molecular Response Kinetics Compared with Imatinib in Patients (Pts) with Newly Diagnosed Chronic Myeloid Leukemia (CML).

Andreas Hochhaus, MD, Giuseppe Saglio, MD, PhD, Richard A. Larson, MD, Dong-Wook Kim, MD, PhD, Ian W. Flinn, MD, PhD, Yeow-Tee Goh, MBBS, MD, Pedro Enrique Dorlhiac-Llacer, MD, Kimmo Porkka, MD, PhD, Mineo Kurokawa, MD, PhD, Carmino DeSouza, MD, PhD, Yaping Shou, MD, PhD, Neil J. Gallagher, MD, PhD, Ariful Haque, Hagop Kantarjian, MD, Timothy P. Hughes, MD, MBBS

Blood (2010) 116 (21): 3431.

https://doi.org/10.1182/blood.V116.21.3431.3431

Published: 2010

Journal Articles

ENESTnd Update: Continued Superiority of Nilotinib Versus Imatinib In Patients with Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP)

Timothy P. Hughes, MD, MBBS, Andreas Hochhaus, MD, Giuseppe Saglio, Dong-Wook Kim, MD, PhD, Saengsuree Jootar, MD, Philipp D. le Coutre, MD, Josy Reiffers, Ricardo Pasquini, MD, Clarisse Lobo, MD, Richard E. Clark, MD, Neil J. Gallagher, MD, PhD, Albert Hoenekopp, MD, Ariful Haque, Richard A. Larson, MD, Hagop M. Kantarjian, MD

Blood (2010) 116 (21): 207.

https://doi.org/10.1182/blood.V116.21.207.207

Published: 2010

Journal Articles

Response and Outcomes to Nilotinib at 24 Months in Imatinib-Resistant Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP) and Accelerated Phase (CML-AP) with and without BCR-ABL Mutations.

Jerald P. Radich, MD, Giovanni Martinelli, MD, Andreas Hochhaus, MD, Enrico Gottardi, Simona Soverini, PhD, Susan Branford, PhD, Martin C Müller, MD, Lan Beppu, Yaping Shou, MD, PhD, Ariful Haque, MS, Richard C. Woodman, MD, Hagop M. Kantarjian, MD, Timothy P. Hughes, MD, MBBS, Dong-Wook Kim, MD, PhD, Giuseppe Saglio, MD

Blood (2009) 114 (22): 1130.

https://doi.org/10.1182/blood.V114.22.1130.1130

Published: 2009

Journal Articles

Molecular Response at 3 Months On Nilotinib Therapy Predicts Response and Long-Term Outcomes in Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia in Chronic Phase (CML-CP).

Susan Branford, PhD, Dong-Wook Kim, MD, PhD, Simona Soverini, PhD, Enrico Gottardi, Lan Beppu, Martin C Müller, MD, Ariful Haque, MS, Yaping Shou, MD, PhD, Richard C. Woodman, MD, Hagop M. Kantarjian, MD, Giovanni Martinelli, MD, Jerald P. Radich, MD, Giuseppe Saglio, MD, Timothy P. Hughes, MD, MBBS, Andreas Hochhaus, MD

Blood (2009) 114 (22): 3292.

https://doi.org/10.1182/blood.V114.22.3292.3292

Published: 2009

Journal Articles

Nilotinib Demonstrates Superior Efficacy Compared with Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase: Results From the International Randomized Phase III ENESTnd Trial

Giuseppe Saglio, Dong-Wook Kim, MD, PhD, Surapol Issaragrisil, MD, FRCP, FACP, FRCPA, FRCPath, Philipp D. le Coutre, MD, Josy Reiffers, MD, Clarisse Lobo, MD, Ricardo Pasquini, MD, Richard E. Clark, MD, Timothy P. Hughes, MD, MBBS, Andreas Hochhaus, MD, Neil J. Gallagher, MD, PhD, Albert Hoenekopp, MD, Mei Dong, MD, MS, Ariful Haque, MS, Hagop M. Kantarjian, MD, Richard A. Larson, MD

Blood (2009) 114 (22): LBA-1.

https://doi.org/10.1182/blood.V114.22.LBA-1.LBA-1

Published: 2009

Journal Articles

Minimal Cross-Intolerance Between Nilotinib and Imatinib in Patients with Imatinib-Intolerant Chronic Myeloid Leukemia in Chronic Phase (CML-CP) or Accelerated Phase (CML-AP)

Elias Jabbour, MD, Hagop M Kantarjian, Michele Baccarani, MD, Philipp D. le Coutre, MD, Ariful Haque, Neil J. Gallagher, MD, PhD, Jorge Cortes, MD, Francis Giles, MD

Blood (2008) 112 (11): 3215.

https://doi.org/10.1182/blood.V112.11.3215.3215

Published: 2008

Journal Articles

Nilotinib Efficacy According to Baseline BCR-ABL Mutations in Patients with Imatinib-Resistant Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

Andreas Hochhaus, MD, Dong-Wook Kim, MD, PhD, Giovanni Martinelli, MD, Timothy P. Hughes, MD, Simona Soverini, PhD, Susan Branford, PhD, Martin C Müller, MD, Philipp Erben, MD, Ariful Haque, Yaping Shou, MD, PhD, Giuseppe Saglio, MD, Jerald P. Radich, MD

Blood (2008) 112 (11): 3216.

https://doi.org/10.1182/blood.V112.11.3216.3216

Published: 2008

Journal Articles

Nilotinib in Chronic Myeloid Leukemia Patients in Accelerated Phase (CML-AP) with Imatinib Resistance or Intolerance: 2-Year Follow-up Results of a Phase 2 Study

Philipp D. le Coutre, MD, Francis Giles, MD, Andreas Hochhaus, MD, Jane F. Apperley, MBChB, FRCP, FRCPath, Gert Ossenkoppele, MD, PhD, Ariful Haque, Neil J. Gallagher, MD, PhD, Michele Baccarani, MD, Jorge Cortes, MD, Hagop M Kantarjian

Blood (2008) 112 (11): 3229.

https://doi.org/10.1182/blood.V112.11.3229.3229

Published: 2008

Journal Articles

Efficacy and Tolerability of Nilotinib in Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP) Who Failed Prior Imatinib and Dasatinib Therapy: Updated Results of a Phase 2 Study

Francis Giles, MD, Philipp D. le Coutre, MD, Kapil N. Bhalla, MD, Gert J Ossenkoppele, MD, PhD, Giuliana Alimena, MD, Ariful Haque, M.S., Neil J. Gallagher, MD, PhD, Hagop M Kantarjian

Blood (2008) 112 (11): 3234.

https://doi.org/10.1182/blood.V112.11.3234.3234

Published: 2008

Journal Articles

Nilotinib in Chronic Myeloid Leukemia Patients in Chronic Phase (CMLCP) with Imatinib Resistance or Intolerance: 2-Year Follow-up Results of a Phase 2 Study.

Hagop M Kantarjian, Francis Giles, MD, Kapil N. Bhalla, MD, Richard A. Larson, MD, Norbert Gattermann, MD, Oliver G. Ottmann, MD, Ariful Haque, M.S., Neil J. Gallagher, MD, PhD, Michele Baccarani, MD, Philipp D. le Coutre, MD

Blood (2008) 112 (11): 3238.

https://doi.org/10.1182/blood.V112.11.3238.3238

Published: 2008

Journal Articles

Nilotinib Is Associated with Minimal Cross Intolerance to Imatinib in Patients with Imatinib-Intolerant Philadelphia-Positive (Ph+) Chronic Myelogenous Leukemia (CML) in Either Chronic Phase (CP) or Accelerated Phase (AP).

Jorge Cortes, MD, Elias Jabbour, MD, Andreas Hochhaus, MD, Philipp le Coutre, MD, Michele Baccarani, MD, Kapil N. Bhalla, MD, Gert Ossenkoppele, MD, PhD, Norbert Gattermann, MD, PhD, Ariful Haque, Neil Gallagher, Francis Giles, MD, Hagop M. Kantarjian, MD

Blood (2007) 110 (11): 1040.

https://doi.org/10.1182/blood.V110.11.1040.1040

Published: 2007

Journal Articles

Nilotinib in Patients (pts) with Relapsed/Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Who Are Resistant or Intolerant to Imatinib.

Oliver G. Ottmann, MD, Richard A. Larson, MD, Hagop M. Kantarjian, MD, Philipp le Coutre, MD, Michele Baccarani, MD, Ariful Haque, Neil Gallagher, Francis Giles, MD

Blood (2007) 110 (11): 2815.

https://doi.org/10.1182/blood.V110.11.2815.2815

Published: 2007

Journal Articles

Nilotinib in Patients (pts) with Philadelphia Chromosome-Positive (Ph+) Chronic Myelogenous Leukemia in Blast Crisis (CML-BC) Who Are Resistant or Intolerant to Imatinib.

Francis J. Giles, MB, MD, FRCPI, FRCPath, Richard A. Larson, MD, Hagop M. Kantarjian, MD, Philipp le Coutre, Michele Baccarani, MD, Ariful Haque, Neil Gallagher, Oliver G. Ottmann, MD

Blood (2007) 110 (11): 1025.

https://doi.org/10.1182/blood.V110.11.1025.1025

Published: 2007

Journal Articles

Nilotinib Therapy after Dasatinib Failure in Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia (CML) in Chronic Phase (CP), Accelerated Phase (AP) or Blast Crisis (BC).

Francis J. Giles, MB, MD, FRCPI, FRCPath, Philipp le Coutre, MD, Kapil N. Bhalla, MD, Gert Ossenkoppele, MD, PhD, Giuliana Alimena, Ariful Haque, Neil Gallagher, Hagop M. Kantarjian, MD

Blood (2007) 110 (11): 1029.

https://doi.org/10.1182/blood.V110.11.1029.1029

Published: 2007

Journal Articles

Correlation of Clinical Response to Nilotinib with BCR-ABL Mutation Status in Advanced Phase Chronic Myelogenous Leukemia (CML-AP) Patients with Imatinib-Resistance or Intolerance.

Giuseppe Saglio, Dong-Wook Kim, Andreas Hochhaus, Simona Soverini, P. Erben, Susan Branford, Ariful Haque, Neil Gallagher, Yaping Shou, Timothy Hughes, G. Martinelli, Jerald Radich

Blood (2007) 110 (11): 1940.

https://doi.org/10.1182/blood.V110.11.1940.1940

Published: 2007

Journal Articles

Nilotinib Is Highly Active and Safe in Chronic Phase Chronic Myelogenous Leukemia (CML-CP) Patients with Imatinib-Resistance or Intolerance.

Hagop M. Kantarjian, MD, Andreas Hochhaus, MD, Jorge Cortes, MD, Giovanni Martinelli, MD, Kapil N. Bhalla, MD, Francis J. Giles, MB, MD, FRCPI, FRCPath, Gert Ossenkoppele, MD, PhD, Norbert Gattermann, MD, PhD, Ariful Haque, Neil Gallagher, Michele Baccarani, MD, Philipp le Coutre, MD

Blood (2007) 110 (11): 735.

https://doi.org/10.1182/blood.V110.11.735.735

Published: 2007

Journal Articles

Nilotinib Is Safe and Effective in Accelerated Phase Chronic Myelogenous Leukemia (CML-AP) Patients with Imatinib Resistance or Intolerance.

Philipp le Coutre, MD, Francis J. Giles, MB, MD, FRCPI, FRCPath, Jane Apperley, MD, Oliver G. Ottmann, MD, Norbert Gattermann, MD, PhD, Stephen G. O’Brien, MD, PhD, Kazimierz Kuliczkowski, Richard A. Larson, MD, Dong-Wook Kim, MD, PhD, Ariful Haque, Neil Gallagher, Michele Baccarani, MD, Hagop M. Kantarjian, MD

Blood (2007) 110 (11): 471.

https://doi.org/10.1182/blood.V110.11.471.471

Published: 2007

Journal Articles

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome–positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance

Hagop M. Kantarjian, Francis Giles, Norbert Gattermann, Kapil Bhalla, Giuliana Alimena, Francesca Palandri, Gert J. Ossenkoppele, Franck-Emmanuel Nicolini, Stephen G. O'Brien, Mark Litzow, Ravi Bhatia, Francisco Cervantes, Ariful Haque, Yaping Shou, Debra J. Resta, Aaron Weitzman, Andreas Hochhaus, Philipp le Coutre

Blood (2007) 110 (10): 3540–3546.

https://doi.org/10.1182/blood-2007-03-080689

Published: 2007

Includes: Supplemental data

Journal Articles

A Phase II Study of Nilotinib, a Novel Tyrosine Kinase Inhibitor Administered to Imatinib-Resistant and -Intolerant Patients with Chronic Myelogenous Leukemia (CML) in Chronic Phase (CP).

Philipp le Coutre, MD, Kapil Bhalla, MD, Francis Giles, MD, Michele Baccarani, MD, Gert J. Ossenkoppele, MD, Andreas Hochhaus, MD, Norbert Gattermann, MD, Teresa Rafferty, MD, Ariful Haque, MD, Aaron Weitzman, MD, Hagop Kantarjian, MD

Blood (2006) 108 (11): 165.

https://doi.org/10.1182/blood.V108.11.165.165

Published: 2006

Journal Articles

A Phase II Study of Nilotinib A Novel Tyrosine Kinase Inhibitor Administered to Imatinib-Resistant or Intolerant Patients with Chronic Myelogenous Leukemia (CML) in Accelerated Phase (AP).

Hagop M. Kantarjian, Norbert Gattermann, Andreas Hochhaus, Richard Larson, Teresa Rafferty, Aaron Weitzman, Ariful Haque, Francis Giles, S.G. O’Brien, Philipp le Coutre

Blood (2006) 108 (11): 2169.

https://doi.org/10.1182/blood.V108.11.2169.2169

Published: 2006

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Nilotinib Lowers the Incidence of BCR-ABL Mutations and Improves the Molecular Response Kinetics Compared with Imatinib in Patients (Pts) with Newly Diagnosed Chronic Myeloid Leukemia (CML).

ENESTnd Update: Continued Superiority of Nilotinib Versus Imatinib In Patients with Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP)

Response and Outcomes to Nilotinib at 24 Months in Imatinib-Resistant Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP) and Accelerated Phase (CML-AP) with and without BCR-ABL Mutations.

Molecular Response at 3 Months On Nilotinib Therapy Predicts Response and Long-Term Outcomes in Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia in Chronic Phase (CML-CP).

Nilotinib Demonstrates Superior Efficacy Compared with Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase: Results From the International Randomized Phase III ENESTnd Trial

Minimal Cross-Intolerance Between Nilotinib and Imatinib in Patients with Imatinib-Intolerant Chronic Myeloid Leukemia in Chronic Phase (CML-CP) or Accelerated Phase (CML-AP)

Nilotinib Efficacy According to Baseline BCR-ABL Mutations in Patients with Imatinib-Resistant Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

Nilotinib in Chronic Myeloid Leukemia Patients in Accelerated Phase (CML-AP) with Imatinib Resistance or Intolerance: 2-Year Follow-up Results of a Phase 2 Study

Efficacy and Tolerability of Nilotinib in Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP) Who Failed Prior Imatinib and Dasatinib Therapy: Updated Results of a Phase 2 Study

Nilotinib in Chronic Myeloid Leukemia Patients in Chronic Phase (CMLCP) with Imatinib Resistance or Intolerance: 2-Year Follow-up Results of a Phase 2 Study.

Nilotinib Is Associated with Minimal Cross Intolerance to Imatinib in Patients with Imatinib-Intolerant Philadelphia-Positive (Ph+) Chronic Myelogenous Leukemia (CML) in Either Chronic Phase (CP) or Accelerated Phase (AP).

Nilotinib in Patients (pts) with Relapsed/Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Who Are Resistant or Intolerant to Imatinib.

Nilotinib in Patients (pts) with Philadelphia Chromosome-Positive (Ph+) Chronic Myelogenous Leukemia in Blast Crisis (CML-BC) Who Are Resistant or Intolerant to Imatinib.

Nilotinib Therapy after Dasatinib Failure in Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia (CML) in Chronic Phase (CP), Accelerated Phase (AP) or Blast Crisis (BC).

Correlation of Clinical Response to Nilotinib with BCR-ABL Mutation Status in Advanced Phase Chronic Myelogenous Leukemia (CML-AP) Patients with Imatinib-Resistance or Intolerance.

Nilotinib Is Highly Active and Safe in Chronic Phase Chronic Myelogenous Leukemia (CML-CP) Patients with Imatinib-Resistance or Intolerance.

Nilotinib Is Safe and Effective in Accelerated Phase Chronic Myelogenous Leukemia (CML-AP) Patients with Imatinib Resistance or Intolerance.

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome–positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance

A Phase II Study of Nilotinib, a Novel Tyrosine Kinase Inhibitor Administered to Imatinib-Resistant and -Intolerant Patients with Chronic Myelogenous Leukemia (CML) in Chronic Phase (CP).

A Phase II Study of Nilotinib A Novel Tyrosine Kinase Inhibitor Administered to Imatinib-Resistant or Intolerant Patients with Chronic Myelogenous Leukemia (CML) in Accelerated Phase (AP).

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only